Doximity (DOCS): the professional network for US doctors
2026-06-22 · By Lubin Danilo, founder of Lubin Investment
Doximity is the LinkedIn for American physicians, with a dominant position that is nearly impossible to replicate: 80% of US doctors use the platform. Its business model generates some of the highest cash margins in tech, and our scoring framework gives it a perfect score. The current valuation remains accessible for this level of quality.
- Doximity connects more than 600,000 American physicians (80% of the profession), a network that cannot be duplicated.
- The business model relies on targeted pharmaceutical advertising and SaaS tools (secure messaging, telemedicine, digital signatures).
- Free cash flow margin exceeds 40%, a level found only among the world's best technology companies.
- Our scoring framework gives Doximity a perfect score of 10 out of 10, which is extremely rare in our database.
- The valuation, around 18 times annual cash generated, remains reasonable for a company of this quality.
- Key risks: dependence on pharma ad budgets, regulatory pressure on health data, and competition from electronic health record systems.
What exactly is Doximity?
Imagine a professional network, a bit like LinkedIn, but reserved exclusively for American healthcare professionals. That is exactly what Doximity is. Founded in 2010 in San Francisco, the company spent over a decade building something unique: a community where 8 out of 10 US physicians have an active profile. In absolute numbers, that is more than 600,000 physicians, plus hundreds of thousands of nurses, pharmacists, and other healthcare professionals.
Why do doctors use Doximity? Because the platform gives them practical tools they cannot find anywhere else: HIPAA-compliant secure messaging (HIPAA being the US law governing medical data privacy), an integrated telemedicine system, digital signature tools for prescriptions and administrative documents, and a physician referral network. In other words, Doximity is not a gadget, it is a daily work infrastructure. And once a physician is used to it, they do not leave.
This is precisely what creates what we call a moat, or competitive ditch. This concept describes what protects a business from competition. Here, the moat is two-sided: network effects (a physician joins Doximity because their colleagues are already there) and switching costs (leaving the platform means losing your contacts, your work habits, and your integrated tools). The result: Doximity has privileged access to virtually the entire US medical profession, a strategic asset that neither startups nor tech giants have managed to replicate in fifteen years.
How does Doximity make money?
Doximity's business model rests on two pillars. The first, and by far the most important, is pharmaceutical advertising. Drug companies pay to deliver their messages directly to prescribing physicians via the platform. This is an extremely targeted form of medical marketing: instead of sending a sales representative to every doctor, a pharmaceutical company can reach precisely the specialists who prescribe in its therapeutic category. The effectiveness is documented, and the budgets allocated to this type of communication are considerable in the pharmaceutical industry.
The second pillar is SaaS, meaning software subscriptions paid by hospitals, medical groups, and healthcare facilities to access telemedicine tools, physician recruitment modules, and internal communication solutions. This subscription model generates regular, predictable revenue. The combination of the two streams (pharmaceutical advertising and SaaS) produces a remarkable financial engine: very low variable costs (the platform costs almost nothing to run once built) and revenues that grow year after year without requiring massive reinvestment.
The result is visible directly in the margins. Doximity's free cash flow margin exceeds 40%. To understand what that means in concrete terms: out of every 100 dollars of revenue, the company keeps more than 40 in real cash, after paying everything. For comparison, a typical industrial company sits between 5 and 10%. Even in tech, reaching 40% FCF margin is exceptional. You find this level only at companies like Microsoft, Visa, or Veeva.
| Metric | Doximity (DOCS) | Medical SaaS sector median | S&P 500 median |
|---|---|---|---|
| FCF margin | > 40% | ~15% | ~12% |
| Quality score (our framework) | 10 / 10 | ~6 / 10 | ~5 / 10 |
| Valuation (P/FCF) | 18.38x | ~35x | ~25x |
| US physician market share | ~80% | fragmented | N/A |
| Revenue growth | steady, +10-15% / year | variable | ~8% / year |
| Debt dependence | nearly zero | moderate | moderate |
The scoring method and the perfect score
At Lubin Investment, every company goes through a ten-criteria financial framework. Each criterion is worth one point. The goal is simple: compare very different companies on the same scale, without emotional bias or sector trends. The criteria cover revenue growth, profitability, free cash flow generation, balance sheet quality, shareholder dilution, return on invested capital, performance consistency, resilience in difficult periods, relative valuation, and management quality.
Doximity scores ten out of ten. This is not a common result. Across all companies analyzed in our database, only a handful reach this score. Concretely, it means the company validates each of the ten criteria without exception: its growth is steady, its margins are among the highest in the listed universe, it generates abundant free cash, its balance sheet carries virtually no debt, it buys back its own shares rather than diluting shareholders, and its return on invested capital is excellent. A score of ten out of ten does not mean the stock will go up tomorrow. It means the intrinsic quality of the business is at the highest level we can observe.
Valuation: what trading at 18x cash actually means
To assess whether a stock is expensive or cheap, I primarily use the P/FCF ratio, that is the price the market is willing to pay for each dollar of free cash flow generated by the company. Doximity currently trades at 18.38 times its annual cash. To put that in context: a valuation of 18x for a medical SaaS company with 80% market share and 40% margins is what I would call quality valuation without excess. The market is not paying for it like a bubble. It is paying for it like a solid, well-established company whose growth is predictable.
For perspective: Adobe, a high-quality company in creative software, traded at an average of 33x its cash over five years. Hypergrowth SaaS platforms can reach 60 to 100x. Doximity, at 18x, sits in a valuation zone I would describe as reasonable for this quality level. It is not cheap, but it is not a bet on future growth at any price either. The market is valuing what the company generates today, with a moderate premium for predictability.
With a market capitalization between 10 and 12 billion dollars, Doximity remains a technology midcap. Large enough not to go unnoticed, but compact enough that growth can still have a meaningful impact on the valuation in the years ahead.
Risks to understand before investing
No perfect company exists, and Doximity is no exception. Three risks deserve clear understanding. The first is dependence on pharmaceutical advertising budgets. The bulk of Doximity's revenue comes from pharmaceutical companies. If pharma marketing spending contracts due to regulatory restriction, sector-wide strategy shifts, or an economic slowdown, Doximity's revenues can be meaningfully affected. This risk is not theoretical: it is what happened in 2023, when drug companies rationalized their spending after the post-COVID boom.
The second risk is regulatory. The platform handles sensitive health data under a strict framework, the HIPAA law. Any change in US medical data privacy regulations, or any security incident, could erode user trust and create costly legal obligations. This risk exists, but it is mitigated by the fact that Doximity was built from the outset with HIPAA compliance at the core of its architecture.
The third risk is competition from electronic health record systems (EHR). Players like Epic or Oracle Health (formerly Cerner) already manage parts of physicians' workflows. If these platforms decided to integrate professional networking or secure communication features, they could chip away at Doximity's territory. This scenario remains unlikely in the short term (these companies have different priorities), but it is a structural risk worth monitoring.
What I take away from Doximity
Doximity embodies what I look for when analyzing a stock: a dominant position that is hard to attack, a business model that generates abundant cash, a management team that allocates that cash intelligently, and a valuation that does not require excessive optimism to be justified. This is not the kind of stock that will triple in six months. It is the kind of stock that can perform steadily for ten years, with little existential volatility.
The perfect score from our framework is not a blind invitation to buy. It says that the quality of the business is at the highest level we can observe. The investment decision then depends on your own time horizon, risk tolerance, and personal entry price. What I can say is that the Doximity case deserves close attention from anyone interested in quality technology stocks with a strong moat. If you want to build a portfolio of durable companies, Doximity is exactly the type of business we are talking about.
FAQ
What is Doximity in one sentence?
Doximity is the digital professional network for American physicians: 80% of them use it for secure communication, telemedicine, and daily workflow management.
How does Doximity make money?
Primarily through targeted pharmaceutical advertising (drug companies pay to reach prescribing physicians) and SaaS subscriptions sold to hospitals and medical groups.
What is FCF margin and why does it matter?
FCF margin (free cash flow) measures the share of revenue that turns into real cash after all expenses. Doximity exceeds 40%, meaning the company is an exceptionally efficient cash-generating machine.
Is Doximity a risky stock?
It carries real risks: dependence on pharma budgets, regulatory risk on health data, and potential competition from EHR systems. But its dominant position and near-zero debt levels limit structural risk.
What does a P/FCF of 18x mean?
It means the market values the stock at 18 times the annual cash generated by the company. For a business of this quality with 80% market share, that is a moderate valuation: neither cheap nor excessively expensive.
Why does Doximity score 10 out of 10?
Because it validates all ten criteria in our framework without exception: steady growth, high margins, abundant cash, healthy balance sheet, share buybacks, excellent return on capital. This is rare and meaningful.
Is this a buy recommendation?
No. This analysis is for informational and educational purposes only. We do not know your personal situation, investment horizon, or risk tolerance. Always do your own research.
Voir l'analyse DOCS sur Lubin Investment
About the author
Written by Lubin Danilo, founder of Lubin Investment. A self-taught individual investor, I have analyzed stocks through their fundamentals for several years and invest my own money with this method. I codified it into a tool that judges a company's quality and its price separately, using criteria drawn from the financial literature (Warren Buffett, Michael Mauboussin, Aswath Damodaran).